Disease · MONDO_0006181

digestive system carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. digestive system carcinoma. Diseases, record MONDO_0006181. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006181

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: digestive system carcinoma; Open Targets
Open Targets ID: MONDO_0006181; Open Targets
Other names: carcinoma of digestive system, carcinoma of the gastrointestinal system, gastrointestinal carcinoma, gastrointestinal carcinoma (disease), gastrointestinal system carcinoma; Open Targets
Disease Ontology: DOID:0050922; Disease Ontology
NCI Thesaurus: C96963; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 2 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
S1?	CHEMBL4525128		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 1	ClinicalTrials.gov	2	2	2	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
GANETESPIB	CHEMBL2103879	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TYMS	Thymidylate synthase	3	Thymidylate synthase inhibitor	Phase 1	https://conductscience.org/library/genes/7298	Drugs and targets
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 antagonist	Phase 1	https://conductscience.org/library/genes/5133	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 1	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	1	GAR transformylase inhibitor	Phase 1	https://conductscience.org/library/genes/2618	Drugs and targets
GUCY2C	Guanylyl cyclase C	1	Heat-stable enterotoxin receptor binding agent	Phase 1	https://conductscience.org/library/genes/2984	Drugs and targets
HDAC1	Histone deacetylase 1	1	Histone deacetylase 1 inhibitor	Phase 1	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase 2	1	Histone deacetylase 2 inhibitor	Phase 1	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase 3	1	Histone deacetylase 3 inhibitor	Phase 1	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Protein deacetylase HDAC6	1	Histone deacetylase 6 inhibitor	Phase 1	https://conductscience.org/library/genes/10013	Drugs and targets
HSP90AA1	Heat shock protein HSP90	1	Heat shock protein HSP90 inhibitor	Phase 1	https://conductscience.org/library/genes/3320	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02937116	First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors	Phase 1	233	2021-02-21	Cancer, Solid Tumor	CAPECITABINE, CISPLATIN, ETOPOSIDE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, OXALIPLATIN, PEMETREXED, SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT03449030	A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)	Phase 1	31	2021-03-22	Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies	TAK-164	Its record names the disease	ClinicalTrials.gov
NCT02391038	MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	Phase 1	12	2017-03-29	Advanced Gastrointestinal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Gastrointestinal Carcinoma	INDUSATUMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT02192541	Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas	Phase 1	5	2018-01-30	Neoplasms	AFLIBERCEPT, GANETESPIB	Its record names the disease	ClinicalTrials.gov
NCT01608646	Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer	Phase 2	200		Gastrointestinal Cancer	OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00003046	Interleukin-12 in Treating Patients With Cancer in the Abdomen	Phase 1	29		Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer	INTERLEUKIN-12 HUMAN RECOMBINANT	Its record names the disease	ClinicalTrials.gov
NCT04932187	Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)	Phase 1	20		Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)	CAMRELIZUMAB, CAPECITABINE	Its record names the disease	ClinicalTrials.gov
NCT00455351	Vorinostat and Palliative Radiotherapy	Phase 1	15		Pelvic Cancer, Radiotherapy	VORINOSTAT	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg vs Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg: Number of Participants Who Had a Dose Limiting Toxicity (DLT)	0 of 2	0 of 3	5	NCT02192541	Trial comparisons
Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg vs Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg: Number of Participants With Serious and Non-serious Adverse Events Regardless of Attribution Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0	2 of 2	3 of 3	5	NCT02192541	Trial comparisons
Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg vs Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg: deaths from any cause	1 of 2	2 of 3	5	NCT02192541	Trial comparisons
Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg vs Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg: serious adverse events	1 of 2	2 of 3	5	NCT02192541	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33070260	RESULT	1	PubMed
32795349	RESULT	1	PubMed
20378407	RESULT	1	PubMed
41121239	DERIVED	1	PubMed
36738333	DERIVED	1	PubMed
35747712	DERIVED	1	PubMed
35647908	DERIVED	1	PubMed
34659886	DERIVED	1	PubMed
32788205	DERIVED	1	PubMed
32372672	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006181

GET https://conductscience.org/api/diseases/v1/MONDO_0006181/targets?page=2

API reference For AI assistants